April 03, 2017
Wellesley, Mass., April 03, 2017 – New proprietary research by BCC Research reveals that new technologies in vaccines and therapeutics and educational efforts to promote prophylactic use of influenza products are driving growth in the global influenza market, which is expected to reach $6.4 billion in 2021, up from $5.4 billion in 2016.
BCC Research's The Global Influenza Market reports that an aging population is another key market driver, boosting sales for products directed at preventive measures, while the international market continues to show promise in vaccination, treatment and diagnosis.
"The 2009 pandemic generated attention to surveillance measures, pandemic preparedness, vaccine production and antiviral control," says Kevin Fitzgerald, BCC Research editorial director. "It also revealed issues with laboratory capacity and the benefits of rapid testing in a pandemic situation."
Threat of Pandemic Keeps Market Growing
Annually, up to a half-million people die of influenza and, with the threat of a pandemic in any given year, government agencies and disease prevention organizations are devoted to gaining control of the situation.
"Many companies have been asked to assist with the problem and others are furthering their position with backing from government agencies," notes Fitzgerald. " The next five years should see support and funding for many research and development programs, product development, and pandemic prevention and/or control by worldwide governments, organizations, and health professionals."
Editors and reporters who wish to speak with the analyst should contact Steven Cumming at firstname.lastname@example.org.
The Global Influenza Market( PHM049D )
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email email@example.com or visit www.bccresearch.com/media to request access to our library of market research.